TrialWatch July/August, 2008

Courtesy of the NIDDK

Prospective assessment in newborns for diabetes autoimmunity

Clinicaltrials.gov Identifier: NCT00649246

This NIH study is looking at genetic and environmental factors that may determine who gets type 1 diabetes. Organized by the NIDDK and universities around the country, this is a large (read: huge) study that involves a number of patients over many years. Despite the ‘newborns’ in the title, many different people can enroll—adults, children, and babies with type 1 diabetes, and even people without diabetes. As a participant, you will probably be checking in with the people at the NIH every once in awhile, but there is no intensive monitoring or therapy involved. Studies like this one are extremely important to the understanding of type 1 diabetes, and we encourage everyone who can to get involved. The trial is currently enrolling in Florida and South Carolina. For more information, you can check out the link above or contact Diane Hopkins at 706-721-4161 or at dhopkins@mcg.edu.

Insulin glargine “all to target” trial

Clinicaltrials.gov Identifier: NCT00384085

This trial is investigating the effectiveness of treatment either with basal insulin (Lantus) and mealtime insulin (Apidra), or with premixed insulin (Novolog Mix 70/30). The trial is enrolling type 2 patients between 30 and 80 years old with an A1c of 7.5% or above, and it lasts for 60 weeks. As a participant, you will be placed on an insulin treatment program involving at least one (and likely two or three) daily injections. You will have to test your blood glucose regularly, and your glucose levels and A1c will occasionally be measured by the trial staff. This trial is recruiting in New Jersey. For more information you can contact the Public Registry USMA of Sanofi-Aventis at PublicRegistryUSMA@sanofi-aventis.com.

Mobile communication technology for adolescents with diabetes

Clinicaltrials.gov Identifier: NCT00605839

We know that having a child or adolescent with diabetes—let alone being one—is tough. Managing glucose levels can be a difficult and time-intensive process, and it may cause problems between parents and their children with diabetes. This trial, enrolling type 1 patients aged 14-18 years old, is looking at a new way to monitor glucose levels using an integrated cell phone and glucose monitor called GlucoPak. People who participate will be given a GlucoPak device and monitored closely over six months. Interestingly, the main purpose of the study is to find out if this new device will improve the relationship between the participant and his or her parents. The researchers will also be watching to see whether blood sugar control changes using GlucoPak. The trial is recruiting in Indiana. For more information you can contact Kelly Haberkorn at 317-278-0552 or klhaberkorn@insightbb.com.